Caredx, Inc.

Health Care
Medical Specialities
www.caredx.com

Moat Score

Market Cap $1.30B
PE -9
Debt $0.00
Cash $95.99M
EV $1.21B
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$143.56M
EBIT	-$143.25M
ROE	-53%
ROA	-30%
Equity	$273.25M
Growth Stability	1
PE	-9.09
PB	4.77
P/S	4.17
Price/Cash	0.07
Debt/Equity	0
Net Margins	-10%
Op. Margins	-46%
Sales Growth QoQ	-10%
Sales CAGR	20%
Equity CAGR	39%
Earnings Growth QoQ	431%
Sales CAGR 5Y	8%

Equity CAGR 5Y	3%
Earnings CAGR 3Y	-4%
Sales CAGR 3Y	-4%
Equity CAGR 3Y	-21%
Market Cap	$1.30B
Revenue	$312.78M
Assets	$476.99M
Total Debt	$0.00
Cash	$95.99M
Shares Outstanding	52.27M
EV	1.21B
Moat Score	4%
Working Capital	252.65M
Current Ratio	4.1
Shares Growth 3y	-1%
Equity Growth QoQ	3%
Equity Growth YoY	-31%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a leading provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.

SEC Filings

Direct access to Caredx, Inc. (CDNA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Caredx, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Caredx, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Caredx, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Caredx, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	08/2023	12/2023	TTM
Net Margins	3%	-49%	-98%	-115%	-61%	-17%	-10%	-10%	-24%	-	-68%	-10%
ROA	-	-21%	-49%	-24%	-12%	-16%	-5%	-5%	-14%	-	-41%	-30%
ROE	-	-46%	-201%	933%	-49%	-22%	-7%	-7%	-18%	-	-73%	-53%

Bad Net Margins (-10.3%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	08/2023	12/2023	TTM
Debt over FCF	-	-1.44	-2.74	-3.43	-0	-	-	-	-	-	-	-
Debt over Equity	0.28	0.53	2.37	-8.36	0	0	0	-	-	-	-	0
Growth Stability	-	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	08/2023	12/2023	CAGR 5Y
Revenue YoY growth	-	3%	44%	19%	58%	66%	51%	54%	9%	-	-	8%
Earnings YoY growth	-	-2K%	190%	40%	-16%	-53%	-15%	64%	150%	-	-	-
Equity YoY growth	-	-29%	-33%	-130%	-2K%	3%	180%	68%	-8%	-	-	3%
FCF YoY growth	-	168%	56%	-15%	-58%	-	-	-	-	-	-	-